Transferrin receptor 2 is frequently and highly expressed in glioblastomas

Translational Oncology

Volumn 3, Issue 2, 2010, Pages 123-134

  Calzolari, Alessia ^a   Larocca, Luigi Maria ^b   Deaglio, Silvia ^c   Finisguerra, Veronica ^a   Boe, Alessandra ^a   Raggi, Carla ^a   Ricci Vitani, Lucia ^a   Pierconti, Francesco ^b   Malavasi, Fabio ^c   De Maria, Ruggero ^a   Testa, Ugo ^a   Pallini, Roberto ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RNA; TEMOZOLOMIDE; TRANSFERRIN RECEPTOR 2;

ADJUVANT THERAPY; ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; CANCER CELL CULTURE; CANCER GRADING; CANCER RADIOTHERAPY; CELL HYPOXIA; CELL PROLIFERATION; CELL SUBPOPULATION; CHEMOSENSITIVITY; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIPID RAFT; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; UPREGULATION;

EID: 77953417287     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1539/tlo.09274     Document Type: Article

References (40)

1. Daniels TR, Delgado T, Rodriguez JA, Helguera G, and Penichet ML (2006). The transferrin receptor, part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121, 144-158.
2. Kawabata H, Yang R, Hirama T, Vuong PT, Kawano S, Gombart AF, and Koeffler HP (1999). Molecular cloning of transferrin receptor 2: a new member of the transferrin receptor-like family. J Biol Chem 274, 20826-20832.
3. Kawabata H, Nakamaki T, Ikonomi P, Smith RD, Germani RS, and Koeffler HP (2001). Expression of transferrin receptor 2 in normal and neoplastic hematopoietic cells. Blood 98, 2714-2719.
4. Fleming RE, Migas MC, Holden CC, Waheed A, Britton RS, Tomatsu S, Bacon BR, and Sly W (2000). Transferrin receptor 2: continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis. Proc Natl Acad Sci USA 97, 2214-2219.
5. Camaschella C, Roetto A, Cali A, De Gobbi M, Gorozzo G, Carella M, Majorano N, Totaro A, and Gasparini P (2000). The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 25, 14-15.
6. Roetto A, Totaro A, Piperno A, Piga A, Longo F, Garozzo G, Calì A, De Gobbi M, Gasparini P, and Camaschella C (2001). New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 97, 2555-2560.
7. Calzolari A, Raggi C, Deaglio S, Sposi NM, Stafsnes M, Fecchi K, Parolini I, Malavasi F, Peschle C, Sargiacomo M, et al. (2006). TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci 119, 4486-4498.
8. Calzolari A, Oliviero I, Deaglio S, Mariani G, Biffoni M, Sposi NM, Malavasi F, Peschle C, and Testa U (2007). Transferrin receptor 2 is frequently expressed in cancer cell lines. Blood Cells Mol Dis 39, 82-91.
9. McCarthy BJ and Kruchko C (2005). Consensus conference on cancer registration of brain and central nervous system tumors. Neuro Oncol 7, 196-201.
10. Hegi ME, Diserens AC, Gorlia T, Hamou MF, De Tribolet N, Weller M, Kros JM, Henfellner JA, Maosn W, Mariani L, et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352, 997-1003.
11. Demuth T and Berens ME (2004). Molecular mechanisms of glioma cell migration and invasion. J Neuroncol 70, 217-228.
12. Recht L, Torres CO, Smith TW, Raso V, and Griffin TW (1990). Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J Neurosurg 72, 941-945.
13. Hall WA, Godal A, Juell S, and Fodstad O (1992). In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme. J Neurosurg 76, 838-844.
14. Chirasani SR, Markovic DS, Synowitz M, Eichler SA, Wisniewski P, Kamiska B, Otto A, Wanker E, Schafer M, Chiarugi P, et al. (2008). Transferrin-receptor- mediated iron accumulation controls proliferation and glutamate release in glioma cells. J Mol Med 87, 153-167.
15. Richardson DR (2002). Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol 42, 267-281.
16. Laske DW, Youle RJ, and Oldfield EH (1997). Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3, 1362-1368.
17. Weaver M and Laske DW (2003). Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 65, 3-13.
18. Deaglio S, Capobianco A, Cali A, Bellora F, Alberti F, Righi L, Sapino A, Camaschella C, and Malavasi F (2002). Structural, functional, and tissue distribution analysis of human transferrin receptor-2 by murine monoclonal antibodies and a polyclonal antiserum. Blood 100, 3782-3789.
19. Ricci-Vitiani L, Larocca LM, Lombardi DG, Signore M, Pierconti F, Petrucci G, Montano N, Maira G, and De Maria R (2008). Mesenchymal differentiation of glioblastoma stem cells. Cell Death Diff 9, 1491-1498.
20. Lisanti MP, Tang ZL, and Sargiacomo M (1993). Caveolin forms a hetero-oligomeric protein complex that interacts with an apical GPI-linked protein: implications for the biogenesis of caveolae. J Cell Biol 123, 595-604.
21. Parolini I, Sargiacomo M, Lisanti MP, and Peschle C (1996). Signal transduction and glycophosphatidylinositol-linked proteins (lyn, lck, CD4, CD45, G proteins, and CD55) selectively localize in Triton-insoluble plasma membrane domains of human leukemic cell lines and normal granulocytes. Blood 87, 3783-3794.
22. Burger PC and Scheithauer BW (1993). Atlas of Tumor Pathology. Tumors of the Central Nervous System Vol. 10. Washington, DC: Armed Forces Institute of Pathology, 4-7.
23. Falchetti ML, Pierconti F, Casalbore P, Maggiano N, Levi A, Larocca LM, and Pallini R (2003). Glioblastoma induces vascular endothelial cells to express telomerase in vitro. Cancer Res 63, 3750-3754.
24. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, and De Maria R (2006). Chemotherapy resistance of glioblastoma stem cells. Cell Death Diff 13, 1238-1241.
25. Simons K and Toomre D (2000). Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1, 31-39.
26. Tacchini L, Bianchi L, Bernelli-Zazzera A, and Cairo G (1999). Transferrin receptor induction by hypoxia. J Biol Chem 274, 24142-24146.
27. Toth I, Yuan L, Rogers JT, Boyce H, and Bridges KR (1999). Hypoxia alters iron-regulatory protein-1 binding capacity and modulates cellular iron homeostasis in human hepatoma and erythroleukemia cells. J Biol Chem 274, 4467-4473.
28. Jain RK, Di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, and Batchelor TT (2007). Angiogenesis in brain tumours. Nat Rev Neurosci 8, 610-622.
29. Pallini R, Sorrentino A, Pierconti F, Maggiano N, Faggi R, and Montano N (2006). Telomerase inhibition by stable RNA interference impairs tumor growth and angiogenesis in glioblastoma xenografts. Int J Cancer 118, 2158-2167.
30. Hanninen MM, Haapasalo J, Haapasalo H, Fleming RE, Britton RS, Bacon BR, and Parkkila S (2009). Expression of iron-related genes in human brain and brain tumors. BMC Neurosci 10, 1-9.
31. Bhaskara VK, Panigrahi M, Challa S, and Babu PP (2005). Comparative status of activated ERK1/2 and PARP cleavage in human gliomas. Neuropathology 25, 48-53.
32. Lama G, Mangiola A, Anile C, Sabatino G, De Bonis P, Lauriola L, Giannitelli C, La Torre G, Jhanwar-Uniyal M, Sica G, et al. (2007). Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue. Int J Oncol 30, 1333-1342.
33. 2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin Cancer Res 13, 6970-6977.
34. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al. (2007). Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21, 2683-2710.
35. Pallini R, Ricci-Vitani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, et al. (2008). Cancer stem cell analysis and clinical out come in patients with glioblastoma multiforme. Clin Cancer Res 14, 8205-8212.
36. Calzolari A, Oliviero I, and Testa U (2007). Transferrin receptor 2 is emerging as a major player in the control of iron metabolism. Cent Eur J Biol 2, 34-55.
37. Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, Pellin A, Lopez-Guerrero JA, Callaghan R, Benito R, Roldan P, Piquer J, Llacer J, et al. (2005). Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme. Clin Neuropathol 24, 209-218.
38. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, and Jain RK (2001). Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 61, 6020-6024.
39. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3, 177-182.
40. Calzolari A, Deaglio S, Maldi E, Cassoni P, Malavasi F, and Testa U (2009). TfR2 expression in human colon carcinomas. Blood Cells Mol Dis 43, 243-249.